Table 2.

Univariate and Multivariate Cox Regression Analysis of All Patients.^a

Outcome	Univariate				Multivariate
	RFS		OS		RFS		OS
	HR (95% CI)	P	HR (95% CI)	P	HR (95% CI)	P	HR (95% CI)	P
MLKL	0.35 (0.13-0.96)	.04	0.32 (0.14-0.75)	.01	0.41 (0.15-1.12)	.08	0.38 (0.16-0.89)	.03
TNM stage	1.77 (0.76-4.10)	.18	2.09 (1.03-4.25)	<.04	1.33 (0.44-4.02)	.61	2.19 (1.01-4.79)	.05
LVI	3.81 (1.38-10.50)	.01	2.71 (1.12-6.58)	.03	2.36 (0.79-7.02)	.12	1.05 (1.01-1.09)	.02
LNI	1.38 (0.71-2.68)	.34	1.80 (1.05-3.08)	.03	0.64 (0.16-2.64)	.84	1.11 (0.35-3.51)	.86
Grade	1.60 (0.58-4.42)	.36	2.38 (1.06-5.32)	.04	1.81 (0.45-6.34)	<.01	2.76 (1.22-6.25)	.02
CEA	4.63 (1.49-14.38)	<.01	3.01 (1.29-7.05)	.01	4.17 (1.33-13.04)	.01	1.37 (0.45-4.11)	.58

Abbreviations: CEA, carcino embryonie antigen; CI, confidence interval; HR, hazard ratio; MLKL, mixed lineage kinase domain-like protein; LNI, positive lymph node invasion; LVI, lymphovascular invasion; OS, overall survival; RFS, recurrence-free survival; TNM, tumor node metastasis.

^an = 135.

^bBold type denotes statistical significance.